Followers | 579 |
Posts | 24391 |
Boards Moderated | 0 |
Alias Born | 08/15/2007 |
Tuesday, February 02, 2016 8:51:22 AM
SAN JOSE, Calif., Dec. 8, 2015 /PRNewswire/ -- Viropro, Inc. (OTCBB: VPRO), which has previously announced it will be changing its name to Axxiom, today announced that Ivor Royston, M.D. has agreed to join its Board of Directors effective immediately.
Dr. Royston is a renowned expert in Immuno-Oncology therapies, Viropro believes his value in helping exploit this product category could be significant, especially in light of Viropro's previously announced intention to acquire NovaRx
Dr. Royston will support Viropro's ongoing pursuit of strategic partnerships with pharmaceutical companies and the acquisition of underappreciated assets. He will also play a pivotal role in recruiting senior executives for Viropro
Dr. Royston's background is ideal both for Viropro's long term strategy of building a diversified portfolio of high value assets and the immediate task of completing the clinical development of the NovaRx cancer immunotherapy portfolio
Dr. Royston has also been instrumental in the formation, financing and development of numerous biotechnology companies including Applied Molecular Evolution (acquired by Eli Lilly); Corixa (acquired by GlaxoSmithKline); Dynavax; LigoCyte (acquired by Takeda); Morphotek (acquired by Eisai); Sequana Therapeutics (acquired by Celera); TargeGen (acquired by Sanofi); and Triangle Pharmaceuticals (acquired by Gilead). Dr. Royston currently serves on the Boards of Syndax, Biocept and Viracta. Dr. Royston received his B.A. (1967) and M.D. (1970) degrees from Johns Hopkins University and completed post-doctoral training in internal medicine and medical oncology at Stanford University. From 1990 until 2000, Dr. Royston was the President and Chief Executive Officer of Sidney Kimmel Cancer Center (formerly the San Diego Regional Cancer Center). From 1977 to 1990, he held various positions in academic medicine and cancer center at the University of California, San Diego (UCSD) School of Medicine. In 1994, he received the San Diego Entrepreneur of the Year Award. In 1997, President Clinton appointed Dr. Royston to a six-year term on the National Cancer Advisory Board. In 2006,
Endexx Corporation (EDXC) Leverages Global Market Trends and Legislative Reforms to Spearhead Growth in the Cannabis and Plant-Based Wellness Sectors • EDXC • Mar 27, 2024 3:01 PM
Applied UV, Inc. Announces Pricing of $2.76 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules • AUVI • Mar 27, 2024 2:51 PM
POET and MultiLane Collaborate to Develop High-Speed Pluggable Transceivers for AI Networks • POET • Mar 27, 2024 10:52 AM
Maybacks Global Entertainment Opens 23 More Stations in Important Major Cities • AHRO • Mar 27, 2024 9:00 AM
NxGen Brands Inc. Forecast to Deliver 140% Growth in Q1 2024 • NXGB • Mar 27, 2024 7:30 AM
Kona Gold Beverages, Inc. Strategic Advancements: Covert LLC Introduces Federally Legal D9 Gummies and Revamps Innovative eCommerce Platform, Propelling Toward $12 Million Annual Revenue Goal • KGKG • Mar 26, 2024 8:30 AM